1. Home
  2. MRM vs LEXX Comparison

MRM vs LEXX Comparison

Compare MRM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIROM Healthcare Technologies Inc.

MRM

MEDIROM Healthcare Technologies Inc.

N/A

Current Price

$0.75

Market Cap

7.6M

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$3.33

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRM
LEXX
Founded
2000
2004
Country
Japan
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
8.7M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
MRM
LEXX
Price
$0.75
$3.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
8.7K
121.1K
Earning Date
05-19-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
$32.01
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.73
$0.35
52 Week High
$4.45
$14.37

Technical Indicators

Market Signals
Indicator
MRM
LEXX
Relative Strength Index (RSI) 28.26 35.46
Support Level N/A $0.57
Resistance Level $1.02 $13.63
Average True Range (ATR) 0.05 1.50
MACD -0.02 -0.95
Stochastic Oscillator 19.01 4.58

Price Performance

Historical Comparison
MRM
LEXX

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: